By Ian Walker

 

LONDON--Pharmaceutical giant AstraZeneca PLC (AZN) said Tuesday that a recent trial of Bydureon met the primary safety objectives to not increase cardiovascular risk for patients with Type-2 diabetes.

However, Astra said that while cardiovascular events were observed in the trial, the object of reducing cardiovascular risk wasn't statistically significant.

 

-Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749

 

(END) Dow Jones Newswires

May 23, 2017 02:34 ET (06:34 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Astrazeneca Charts.